Company / Shareholders' Equity
Kiniksa Pharmaceuticals International, plc Shareholders' Equity History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$567.6M
FY2025
5-year range
$225.4M / $567.6M
FY2021-FY2025
Trend
+29.5%
vs FY2024
Sector context
#86 of 213
Health Care
What the data says
At $568M, Kiniksa Pharmaceuticals International, plc's shareholders' equity ranks #86 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 9 years, ranging from -$90M in FY2017 to $568M in FY2025.
Based on SEC 10-K filings.
$568M in FY2025 with a 5-year CAGR of +12.7%.
Improved from $439M to $568M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +12.7%
- 5-Year CAGR
- +12.7%
- 10-Year CAGR
- -
Sector benchmark
#86 of 213 in Health CareTop 40% of 213This company $567.6M Sector average $2.5B
▼
-77.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.7%, indicating consistent growth.
- In FY2025, shareholders' equity increased 29.5% year-over-year.
- Ranks #86 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2017.
Company context
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $567.6M | +29.5% |
| FY2024 | $438.4M | -0.1% |
| FY2023 | $438.8M | +10.8% |
| FY2022 | $396.1M | +75.7% |
| FY2021 | $225.4M | -27.7% |
| FY2020 | $311.9M | +38.4% |
| FY2019 | $225.4M | -19.3% |
| FY2018 | $279.3M | +411.3% |
| FY2017 | -$89.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026